The Capio Prostate Cancer Center Model for Prostate Cancer Diagnostics-Real-world Evidence from 2018 to 2022.

ABSTRACT:

Background

The Capio Prostate Cancer Center (Capio PCC) in Stockholm, Sweden, adopts a comprehensive diagnostic approach, utilizing prostate-specific antigen (PSA), Stockholm3, and magnetic resonance imaging (MRI) for prostate cancer risk assessment, followed by targeted and systematic biopsies for high-risk cases.

Objective

This study aims to elucidate the clinical process and real-world outcomes of the Capio PCC model for prostate cancer diagnosis at Capio S:t Göran Hospital.

Design setting and participants

Between 2018 and 2022, a cohort of 12 406 men aged 45-75 yr underwent prostate cancer testing, adhering to Capio PCC's structured diagnostic protocol.

Outcome measurements and statistical analysis

We provide a comprehensive description of the Capio PCC mod

SUBMITTER: Palsdottir T 

PROVIDER: S-EPMC10879938 | biostudies-literature | 2024 Mar

REPOSITORIES: biostudies-literature